Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
Fiche publication
Date publication
mars 2018
Journal
Annals of surgical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HEYD Bruno
Tous les auteurs :
Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, De Simone M, Robella M, Heyd B, Kusamura S, Baratti D, Chouliaras K, Russell G, Shen P, Levine EA,
Lien Pubmed
Résumé
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has dramatically improved the survival of patients with epithelioid peritoneal mesothelioma. It is unknown if CRS/HIPEC is indicated for the more aggressive biphasic mesothelioma variant.
Mots clés
Chemotherapy, Adjuvant, Chemotherapy, Cancer, Regional Perfusion, mortality, Combined Modality Therapy, Cytoreduction Surgical Procedures, mortality, Female, Follow-Up Studies, Humans, Hyperthermia, Induced, mortality, Male, Mesothelioma, mortality, Middle Aged, Peritoneal Neoplasms, mortality, Prognosis, Registries, statistics & numerical data, Retrospective Studies, Survival Rate
Référence
Ann. Surg. Oncol.. 2018 Mar;25(3):667-673